Human Psychopharmacology Clinical and Experimental · 2004 · 63 citations · 22 references
MedicinePharmacologyPharmacotherapyEpilepsyNeuropharmacologyPharmacodynamicsAntiepileptic PharmacologyAntiepileptic PharmacotherapySeizure ManagementPharmacodynamic MechanismsPharmacokinetic Interaction MechanismsTopiramate TherapyToxic EncephalopathyValproate PharmacologyValproic Acid
Six severe epileptic patients developed stuporous encephalopathy with marked cognitive impairment when topiramate (TPM) and sodium valproate (VPA) were coprescribed for five patients, and when monotherapy with TPM was introduced for one patient. In four patients, ammonaemia increased and then returned to normal after TPM or VPA withdrawal. This severe potential side effect must be recognized. Moreover two distinct mechanisms might explain this toxicity: (1). a pharmacokinetic interaction between VPA and TPM, leading to hyperammonaemia, (2). a pharmacodynamic mechanism due to a direct toxicity of TPM in at-risk epileptic patients.
22
ADVERSE DRUG REACTION MONITORING: DOING IT THE FRENCH WAY
Nicholas Moore, Gautier Paux, Bernard Bégaud et al. · The Lancet · 1985 · 229 citations
Valproate-induced hyperammonemic encephalopathy in the presence of topiramate
Hajo M. Hamer, Susanne Knake, Ulrich Schomburg et al. · Neurology · 2000 · 171 citations
Asymptomatic Hyperammonemia in Patients Receiving Valproic Acid
J. V. Murphy · Archives of Neurology · 1982 · 129 citations
Sodium Valproate‐induced hyperammonemia without clinical hepatic dysfunction
Bruce S. Zaret, R. Randolph Beckner, Ann M. Marini et al. · Neurology · 1982 · 114 citations